IM Cannabis (IMCC) Competitors

IM Cannabis logo
$2.25 +0.04 (+1.81%)
Closing price 02/14/2025 03:48 PM Eastern
Extended Trading
$2.25 0.00 (0.00%)
As of 02/14/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCC vs. INAB, APRE, OKUR, SNTI, MIRA, LPCN, BCAB, MEIP, MRKR, and CARM

Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Lipocine (LPCN), BioAtla (BCAB), MEI Pharma (MEIP), Marker Therapeutics (MRKR), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.

IM Cannabis vs.

IM Cannabis (NASDAQ:IMCC) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.

IN8bio has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. IM Cannabis' return on equity of -129.86% beat IN8bio's return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-25.55% -129.86% -23.63%
IN8bio N/A -197.15%-130.48%

IN8bio has a consensus price target of $7.75, indicating a potential upside of 2,565.06%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IN8bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IM Cannabis has higher revenue and earnings than IN8bio. IM Cannabis is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$36.15M0.14-$7.04M-$3.41-0.66
IN8bioN/AN/A-$30.01M-$0.75-0.39

In the previous week, IN8bio had 16 more articles in the media than IM Cannabis. MarketBeat recorded 17 mentions for IN8bio and 1 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.00 beat IN8bio's score of 0.49 indicating that IM Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
IM Cannabis Positive
IN8bio Neutral

IN8bio received 19 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 73.53% of users gave IN8bio an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.

CompanyUnderperformOutperform
IM CannabisOutperform Votes
6
42.86%
Underperform Votes
8
57.14%
IN8bioOutperform Votes
25
73.53%
Underperform Votes
9
26.47%

IM Cannabis has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.

Summary

IN8bio beats IM Cannabis on 11 of the 17 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

MetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$5.05M$1.21B$5.84B$9.14B
Dividend YieldN/AN/A5.27%4.00%
P/E Ratio-0.6639.6026.2019.39
Price / Sales0.145.69468.35124.16
Price / CashN/A10.8846.1438.90
Price / Book0.491.917.275.05
Net Income-$7.04M-$53.22M$3.19B$222.74M
7 Day Performance-0.22%1.51%2.82%2.11%
1 Month Performance-7.41%3.23%4.59%2.33%
1 Year Performance27.33%-6.57%22.54%16.79%

IM Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
1.2093 of 5 stars
$2.25
+1.8%
N/A+25.0%$5.05M$36.15M-0.66340Short Interest ↓
Positive News
INAB
IN8bio
3.8728 of 5 stars
$0.27
+3.9%
$7.75
+2,769.3%
-74.0%$19.58MN/A-0.3620Analyst Forecast
Short Interest ↓
News Coverage
Gap Down
APRE
Aprea Therapeutics
2.4374 of 5 stars
$3.59
-6.3%
$15.50
+331.8%
-40.1%$19.49M$580,000.00-1.287Short Interest ↑
OKUR
OnKure Therapeutics
3.3927 of 5 stars
$5.82
-0.5%
$36.00
+518.6%
N/A$19.44MN/A-0.48N/AGap Up
SNTI
Senti Biosciences
2.6695 of 5 stars
$4.02
-3.1%
$10.00
+148.8%
+4.3%$19.38M$2.56M-0.264Short Interest ↑
Negative News
MIRA
MIRA Pharmaceuticals
2.5104 of 5 stars
$1.17
+1.7%
$14.00
+1,096.6%
+0.0%$19.38MN/A-2.092
LPCN
Lipocine
2.0853 of 5 stars
$3.50
flat
$10.00
+185.7%
-11.2%$18.73M$500,000.00-4.6110Short Interest ↑
News Coverage
BCAB
BioAtla
3.5138 of 5 stars
$0.38
-14.4%
$6.00
+1,461.3%
-81.8%$18.58MN/A-0.2360Short Interest ↓
MEIP
MEI Pharma
4.5491 of 5 stars
$2.77
-0.4%
$7.00
+152.7%
-42.9%$18.45M$65.30M-0.40100Earnings Report
Analyst Forecast
Short Interest ↓
Gap Down
MRKR
Marker Therapeutics
4.38 of 5 stars
$1.72
-2.8%
$19.00
+1,004.7%
-57.8%$18.42M$3.31M0.0060Short Interest ↑
Analyst Revision
News Coverage
CARM
Carisma Therapeutics
3.408 of 5 stars
$0.44
-5.2%
$4.94
+1,027.3%
-76.9%$18.30M$14.92M-0.2820Short Interest ↑
Negative News
Gap Down

Related Companies and Tools


This page (NASDAQ:IMCC) was last updated on 2/15/2025 by MarketBeat.com Staff
From Our Partners